Randomized phase II clinical study on preventive effects of GPS, healthy food on the incidence of infection cases in stomach and colon cancer patients before and after the abdominal surgery

Randomized phase II clinical study on preventive effects of GPS, healthy food on the incidence of infection cases in stomach and colon cancer patients before and after the abdominal surgery - Preventive effects of GPS on the incidence of infection cases in cancer patients before and after surgery

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002343

Enrollment

200

Registered

2009-08-17

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stomach and colon cancer patients

Interventions

GPS group 250mg of GPS (a cupsel contain 125mg of GPS) are orally taken continuously for 3 days before operation and for 27days after opperation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are going to take surgical operation on stomac or colon cancer.

Exclusion criteria

Exclusion criteria: 1. Sevier compromised patient(more than PS3) 2. Patient of SHOWKAKAN KYOUSAKU or breading 3. SHINKOUSEI infectious patient 4. Urgent operation patient 5. ZOUKIFUZEN patient 6. Uncontrollable patients together with diabetes mellitus and treated with insulin 7. Suspected cases allergic to yeasts 8. Patient who has been treated with chemotherapy 9. Other patients who are considered to be ruled out by the doctor concerned

Design outcomes

Primary

Measure	Time frame
incidence of Surgical Site Infection	—

Countries

Japan

Contacts

Public ContactTsunesuke Kajimoto, Ph.D.

Nippon Biothera Co., Ltd. Healthcare Division

t.kajimoto@nipponbiothera.co.jp03-5276-0212

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026